Overview

A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)

Status:
Completed

Trial end date:
2010-03-18

Target enrollment:

Participant gender:

Summary

Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of ertugliflozin.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Collaborator:

Pfizer

Treatments:

Ertugliflozin